i agree. i go back to Dr. Kelly's comment from a recent conference call that "in my opinion, this will eventually be an oncology company".

that stuck out to me, because that's a statement that he didn't have to make - but as a guy who knows more about what's going on behind the scenes, and who understands the science as well as anyone, it makes me think the outlook is particularly bright for this drug in oncology, which obviously bodes well for a very high long-term growth trajectory for CYDY.